[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-incontinence":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,79,0,25,[9,41,77,105,128,156,183,212,244,273,298,329,357,381,408,435,460,473,504,529,557,579,604,627,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053595","uk-purewick-at-home-pilot-study-100053595",false,"NCT07555548","UK PureWick™ At-Home Pilot Study","An Open-label Pilot Study Conducted in the UK to Evaluate the Clinical Benefits of the PureWick™ Female External Catheter System Compared to Indwelling Urinary Catheters in Female Patients Receiving Home-based Care","Inclusion Criteria:\n\n1. Adult Female Subjects \\>18 years of age at the time of signing the informed consent.\n2. Treated with indwelling catheters for at least four weeks\n3. Encountered \"problematic catheters\" necessitating a minimum of five interventions within the past month, involving medical treatment and HCP consultation;\n4. Willing to comply with all study procedures in this protocol\n5. The subject (or subject's power of attorney) must be willing and able to read, understand, sign, and date the informed consent form.\n\nExclusion Criteria:\n\nSubjects are excluded from the study if any of the following criteria apply:\n\n1. Has frequent episodes of bowel incontinence without a fecal management system in place; or\n2. Has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or\n3. Has vaginal or other chronic non-urinary tract infections (UTIs), active genital herpes; or\n4. Is agitated, combative, and\u002For uncooperative and may remove the external catheter; or\n5. Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or\n6. Has any pre-existing neurological, psychiatric, or other conditions that would confound quality of life assessment or would make it difficult to self-report on quality-of-life questionnaires in the opinion of the investigator; or\n7. Is known to be pregnant at time of enrollment (for women of childbearing age); or\n8. Has a confirmed diagnosis of urinary tract infection at the time of enrollment.\n9. Subjects with a urine output of ≥1800 mL over a 12-hour period who, or whose caregivers, are unable to independently empty the collection canister.\n10. Any other condition that, in the opinion of the investigator, would preclude them from participating in the study.","FEMALE","18 Years",{"count":20,"type":21},95,"ESTIMATED","OBSERVATIONAL","The UK PureWick™ At-Home Study is being carried out to see how well the PureWick™ Collection System works for women who use it at home instead of a traditional catheter. Traditional catheters are placed inside the body. The PureWick™ Collection System is different, it's placed outside the body .\n\nIn this study, researchers want to find out: how effective the PureWick™ Collection System is in helping women manage urine collection at home, whether patients prefer using PureWick™ Collection System over the usual catheter, how it affects their sleep, and overall well-being.The PureWick™ Collection System is intended for the treatment of patients who leak urine (called urine incontinence). The PureWick™ Collection System is designed to help manage urine in female patients without needing to insert a urinary catheter into the body.",[25],"Urinary Incontinence",[27],"UTI","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2026-05-06",{"date":36,"type":21},"2027-01",{"name":38,"class":39},"Becton, Dickinson and Company","INDUSTRY",4,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100622747","synchronized-core-pelvic-floor-activation-in-urinary-incontinence-100622747","NCT07387640","Synchronized Core-Pelvic Floor Activation in Urinary Incontinence","Synchronized Activation of Core and Pelvic Floor Muscles: A More Effective Strategy for Urinary Incontinence?","Inclusion Criteria:\n\n* Aged between 18 and 65 years\n* Diagnosed with stress, urge, or mixed urinary incontinence\n* Pelvic floor muscle strength grade ≥ 3 according to the Modified Oxford Scale\n* At least one episode of urinary leakage within the last month\n\nExclusion Criteria:\n\n* Pregnancy\n* Childbirth within the previous 6 weeks\n* Severe pelvic organ prolapse\n* Active vaginal or urinary tract infection\n* Presence of neurological or psychiatric disorders\n* Malignancy\n* Inability to cooperate with assessments or interventions","65 Years",{"count":50,"type":21},50,"INTERVENTIONAL",[53],"NA","This study aims to investigate whether co-activation of the pelvic floor and core muscles improves treatment outcomes in individuals with urinary incontinence. Participants diagnosed with stress, or mixed urinary incontinence will undergo a 12-week pelvic floor physiotherapy program, with or without additional core muscle co-activation exercises. Changes in urinary incontinence severity, pelvic floor muscle function, core muscle activation, and quality of life will be evaluated.",[56,57,58,25],"Urinary Incontinence,Stress","Stress Urinary Incontinence","Mixed Incontinence Due to Prolapse of Female Genital Organ",[60,61,62,63,64],"Pelvic floor muscle training","Core stability exercises","Core Muscle Co-activation","Pelvic floor physiotherapy","Surface Electromyography","NOT_YET_RECRUITING","2026-06-30",{"date":68,"type":32},"2026-07-01",{"date":70,"type":21},"2026-08-30",{"date":72,"type":21},"2027-08-30",{"name":74,"class":75},"Bezmialem Vakif University","OTHER",1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":51,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":76},"100633265","improving-the-care-of-incontinence-associated-dermatitis-iad-using-a-beta-glucan-cream-as-a-hydrating-and-soothing-agent-100633265","NCT07524439","Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent","Eligible participants are adults (≥18 years) with IAD secondary to urinary and\u002For fecal incontinence and an expected hospital stay of ≥7 days. Written informed consent will be obtained directly or via substitute decision-maker. Exclusion criteria include absence of IAD or incontinence, pediatric patients, and participants with known hypersensitivities to components of cream (e.g. beta-glucan).","ALL",{"count":85,"type":21},60,[53],"The goal of this clinical trial is to determine whether adding a β-glucan moisturizing cream to routine skin care can enhance skin healing, accelerate visible recovery, reduce discomfort, and improve both patient and clinician experiences. The study will also learn about the safety and tolerability of the β-glucan cream when used along with standard skin care.\n\nThe main questions it aims to answer are:\n\nAre there visible changes in the severity of IAD when β-glucan cream is added to standard care, and if so, to what extent does it reduce severity compared with standard care alone?\n\nDoes the β-glucan cream help IAD heal faster?\n\nDoes the cream reduce symptoms such as pain, itching, tingling, or burning?\n\nWhat medical problems or side effects, if any, do participants experience while using the β-glucan cream?\n\nResearchers will compare standard care plus β-glucan cream to standard care alone to see if the β-glucan cream provides additional benefit for treating IAD.\n\nParticipants will:\n\nReceive either β-glucan cream plus standard care or standard care alone\n\nHave the study cream applied once daily for up to 2 weeks\n\nHave their skin checked weekly by the study team using a standardized assessment tool\n\nAnswer questions about symptoms such as pain, itching, tingling, and burning\n\nAllow photographs of the affected skin area to be taken for secure clinical review\n\nBe monitored for any side effects or skin reactions during the study",[89,25,90,91,92],"Fecal Incontinence","Diaper Rash","Irritant Contact Dermatitis Caused by Faeces","Irritant Contact Dermatitis",[94,95],"Administration, Topical","Administration, Cutaneous","2026-06-23",{"date":98,"type":32},"2026-06-26",{"date":100,"type":32},"2026-05-01",{"date":102,"type":21},"2028-11-30",{"name":104,"class":75},"University of Alberta",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":51,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":76},"100538012","prospective-and-comparative-evaluation-of-a-medical-device-composed-of-a-perineal-probe-connected-to-a-mobile-application-in-the-management-of-stress-urinary-incontinence-100538012","NCT06285292","Prospective and Comparative Evaluation of a Medical Device Composed of a Perineal Probe Connected to a Mobile Application in the Management of Stress Urinary Incontinence.","PRIME","Inclusion Criteria:\n\n* Patients with moderate, severe or very severe stress urinary incontinence or mixed stress urinary incontinence (according to ICIQ-UI SF questionnaire score: moderate (6-12), severe (13-18) and very severe (19-21))\n* Patient aged between 18 and 60\n* Patient with a quality of life score measured with the I-QoL questionnaire less than or equal to 70 (score measured from 0 to 100, with poor quality of life: 0-35; average quality of life: 36-70; good quality of life: 71-100)\n* Not to have given birth in the last 6 months (to avoid post-partum physiological recovery)\n* Signed informed consent\n* Effective contraception throughout the study (declarative)\n* Patient must have a smartphone running at least Android 7 and iOS 12\n* Patient must be able to read and write French\n\nExclusion Criteria:\n\n* Patients with mild stress urinary incontinence or mixed stress urinary incontinence (ICIQ-UI SF score: mild (1-5))\n* Patient with a quality of life score above 70 (according to the I-QoL questionnaire: good quality of life: 71-100)\n* Patient undergoing other pelvic-perineal rehabilitation during the study period\n* Patients with neurological disease or congenital malformation, surgically or medically treated urinary incontinence or prolapse, perineal hypoesthesia or local conditions prohibiting the use of an intravaginal catheter\n* Infection of the bladder or vagina, or any symptoms associated with infection (itching, pain on urination or fever)\n* Contraindications to the use of the medical device\n* Anatomy making catheter placement difficult or impossible; in the case of prolapse, specialist advice is recommended.\n* Hemorrhage\n* Patients with genitourinary cancer (within the last 5 years)\n* Patients with extra-urethral \"incontinence\" (fistula, ectopic ureter)\n* Patients with severe urinary retention\n* Patient with vesico-ureteral reflux\n* Patients with hypoactive bladder\n* In case of peripheral denervation in the pelvic-perineal area, specialist advice is recommended\n* Patients wearing a sacral neuromodulation device\n* Patients in an exclusion period (determined by a previous or current study)\n* Impossibility of giving the subject clear information (subject in an emergency situation, difficulties in understanding the subject, etc.)\n* Patient under court protection\n* Patient under guardianship or curatorship\n* Pregnancy (positive pregnancy test)\n* Breastfeeding (as the hormonal impregnation caused by breastfeeding has a negative impact on perineal tone)\n* Use of Huawei and Oppo smartphones","60 Years",{"count":114,"type":21},138,[53],"Stress urinary incontinence (SUI) affects around 40% of women and has a major impact on quality of life. The gold standard for the treatment of SUI is pelvicfloor rehabilitation, but this presents constraints in terms of availability of healthcare professionals, as well as organization and travel for patients. Innovative devices offer self-training exercises for the pelvicfloor, thus promoting motivation and adherence to treatment. The hypothesis of this study is to prove that the use of a pelvicfloor medical device combined with 2 rehabilitation sessions is not inferior to pelvic-perineal rehabilitation.",[25],[119],"urinary incontinence, pelvic-floor muscles, pelvic-perineal rehabilitation",{"date":121,"type":32},"2026-06-25",{"date":123,"type":32},"2024-11-25",{"date":125,"type":21},"2026-11-25",{"name":127,"class":75},"Nantes University Hospital",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":51,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100381567","adjustable-continence-therapy-act-for-the-treatment-of-female-sui-100381567","NCT04248283","Adjustable Continence Therapy (ACT) for the Treatment of Female SUI","A Clinical Investigation of the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency","Inclusion Criteria:\n\n1. Female at least 22 years old\n2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency\n3. Provocative pad weight of greater than 11.0 grams\n4. Candidate for surgical intervention\n5. Negative urinalysis\n6. Normal cystourethroscopy\n7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent)\n8. Willing and able to sign informed consent and comply with trial follow-up requirements\n\nExclusion Criteria:\n\n1. Pregnant or lactating\n2. Life expectancy of less than 5 years\n3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg\u002FdL\n4. Has auto-immune disease\n5. Undergoing radiation therapy\n6. Active urinary tract infection\n7. Detrusor instability refractory to medication\n8. Reduced bladder compliance as defined by a cystometrogram\n9. Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml\n10. Has, had, or is suspected of having bladder cancer\n11. History of bladder stones\n12. Urethral stricture evidenced during cystourethroscopy\n13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia\n14. Has a diathesis, hemophilia, or a bleeding disorder\n15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher\n16. Had prior pelvic radiotherapy\n17. Had a prior artificial urinary sphincter implanted\n18. Has a neurogenic condition known to affect bladder\u002Fsphincter function","22 Years",{"count":137,"type":21},167,[53],"A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.",[25,56],[25,142,143,144,145],"Urination Disorders","Urination Involuntary","Urologic Diseases","Lower Urinary Tract Symptoms","2026-06-15",{"date":148,"type":32},"2026-06-17",{"date":150,"type":32},"2021-01-26",{"date":152,"type":21},"2032-05-31",{"name":154,"class":39},"Uromedica",5,{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":83,"minAge":4,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":76},"100368519","urinary-disorders-in-subacute-patients-after-stroke-100368519","NCT04078373","Urinary Disorders in Subacute Patients After Stroke","Assessment and Treatment of Urinary Disorders in Patients in the Subacute Phase After Stroke","UIMK","Inclusion Criteria:\n\n* subacute patients after ischaemic or hemorrhagic stroke;\n* direct transfer from acute hospital to complex inpatient rehabilitation at our Institute.\n\nExclusion Criteria:\n\n* incontinence before stroke;\n* previous brain injury or other brain disease;\n* previous bladder or prostate surgery;\n* inability to ambulate before stroke;\n* terminal disease with expected survival less than three months.",{"count":165,"type":21},250,"This observational study will address urinary disorders in subacute stroke patients. Patients without and with urinary disorders will be compared, and treatment outcome will be assessed among the latter.",[168,169,25],"Stroke, Ischemic","Stroke Hemorrhagic",[171,172,173,174],"stroke","inpatient rehabilitation","urinary disorders","treatment","2026-06-11",{"date":146,"type":32},{"date":178,"type":32},"2019-06-01",{"date":180,"type":21},"2026-10",{"name":182,"class":75},"University Rehabilitation Institute, Republic of Slovenia",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":191,"sex":17,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":51,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":76},"100642995","effects-of-a-multimodal-and-multidimensional-intervention-on-urinary-incontinence-in-young-nulliparous-female-athletes-100642995","NCT07644273","Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes.","Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. Single-Center Randomized Controlled Stepped-Wedge Trial","PELVICATHLE","Inclusion Criteria :\n\n* Female subject, nulliparous\n* Member of an athletics club affiliated with the French Athletics Federation (FFA)\n* At least 15 years old at the start of the study and belonging to the U16\u002FU18\u002FU20\u002FU23 categories (born between January 1, 2005, and September 1, 2011)\n* Having internet access\n* Having access to a digital device (computer, tablet, mobile phone)\n* Affiliated with or covered by a social security scheme\n* Having freely given their express consent, as well as the express consent of both parents for minor participants\n\nExclusion Criteria :\n\n* Any individual deprived of their liberty or subject to legal protection (guardianship, curatorship, or protective supervision).\n* A pregnant woman, a woman who has been pregnant, or a woman planning a pregnancy within the last nine months.\n* Any individual unable to understand the purpose and conditions of the study.\n* Any individual unable to give their consent.",true,"15 Years","40 Years",{"count":195,"type":21},198,[53],"A prevalence of urinary incontinence ranging from 5.7% to 80% has been observed in young nulliparous athletes during their activity.\n\nThe usual recommendations for managing adult women do not seem to be transferable.\n\nYoung nulliparous athletes need specific educational and behavioral interventions and an alternative to pelvic floor muscle strengthening.\n\nA multimodal and multidimensional intervention for athletes and coaches combining specific pelvic health education and strengthening of lumbopelvic-abdominal stability appears to be an innovative and optimal solution for reducing the symptoms of urinary incontinence in young nulliparous women who participate in athletics.",[25],[200,201,202],"Urinary incontinence","women's health","track and field","2026-06-08",{"date":205,"type":32},"2026-06-12",{"date":207,"type":21},"2026-09",{"date":209,"type":21},"2027-06",{"name":211,"class":75},"Centre Hospitalier Universitaire de Saint Etienne",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":191,"sex":219,"minAge":18,"maxAge":112,"enrollmentInfo":220,"targetDuration":4,"studyType":51,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100627682","male-pelvic-floor-muscle-rehabilitation-exercises-100627682","NCT07451808","Male Pelvic Floor Muscle Rehabilitation Exercises","Male Pelvic Floor Muscle Rehabilitation (Kegel Exercises) Pelvic Floor Muscle Training","Inclusion Criteria:\n\n* Men 18 - 60 years of age\n* Must be able to achieve an erection\n\nExclusion Criteria:\n\n* Underlying medical conditions or poor health\n* Men who fall within the obese category based on standard body mass index (BMI) measurements","MALE",{"count":221,"type":21},100,[53],"Phase I\n\nG128 Study Objective\n\nThe ischiocavernosus (IC) and bulbospongiosus (BS) muscles are vital components of the superficial perineal layer, serving as the foundation for male sexual health and performance. These muscles play a primary role in achieving and maintaining erections by compressing the veins to trap blood within the erectile tissues. Furthermore, they are responsible for the rhythmic contractions necessary for ejaculation and the physiological sensations associated with orgasm.\n\nBeyond their role in sexual function, these muscles provide critical structural support to the pelvic floor and assist in urinary control. By working in tandem, the IC and BS muscles ensure penile rigidity while stabilizing the surrounding pelvic structures. Maintaining the strength and coordination of these muscles is essential for overall reproductive health and the prevention of pelvic floor dysfunction.\n\nThe primary objective of this clinical trial is to evaluate the clinical efficacy and therapeutic potential of Exercise G128 in strengthening the male pelvic floor musculature. Furthermore, the study aims to establish a comprehensive safety profile for Exercise G128 during active participation. The research seeks to address the following core investigative questions:\n\nTo what extent does Exercise G128 improve the tonicity and contractile strength of the IC and BS muscles?\n\nWhat is the incidence and nature of adverse medical events or physiological stressors reported by participants while performing the Exercise G128 protocol?\n\nResearchers will conduct a comparative analysis, benchmarking the physiological outcomes of Exercise G128 against existing clinical data regarding the efficacy of traditional Kegel exercises.\n\nParticipant Requirements:\n\nAdhere to a structured regimen, performing Exercise G128 four times weekly over a one-month intervention period.\n\nAttend bi-weekly telehealth consultations via video conferencing for supervised clinical assessments, progress monitoring, and physiological testing.\n\nMaintain a detailed daily log documenting functional progress, as well as any instances of physical exertion or soreness that necessitated a temporary cessation of the exercise protocol.",[225,25,226],"Erectile Dysfunction","Premature Ejaculation",[228,229,230,231,232,233,234],"Dripping or leakage","urinary incontinence","Kegel exercises for men","ischiocavernosus muscle","bulbospongiosus muscle","Erectile dysfunction (ED)","Premature ejaculation","2026-06-07",{"date":237,"type":32},"2026-06-10",{"date":239,"type":21},"2026-12",{"date":241,"type":21},"2027-12",{"name":243,"class":75},"Dream Video LLC",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":252,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":51,"phases":255,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":272},"100552987","trial-of-transurethral-bulking-agent-injection-versus-single-incision-sling-for-stress-urinary-incontinence-100552987","NCT06480227","Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","A Randomized Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","BASIS","Inclusion Criteria:\n\n* Women ≥ 21 years\n* For \\> 3 months, bothersome SUI (response of somewhat, moderately, or quite a bit) without UUI or stress-predominant MUI. For those with equal bother of UUI and SUI, clinician determination that SUI is more severe\u002Fsignificant than UUI is required.\n* A positive cough stress test on standardized non-invasive testing or urodynamic SUI within the past 18 months.\n* Normal PVR \\\u003C 150 mL\n* Candidate for either study procedure as determined by treating surgeon\n* Available for up to 3 years.\n* Agrees to randomization.\n\nExclusion Criteria:\n\n* Anterior\u002Fapical vaginal prolapse beyond the hymen (\\>0 on POPQ)\n* Urge-predominant mixed UI despite stable therapy\n* Advanced UUI\u002FOAB 3rd line therapy treatment within 1 year of enrollment.\n* Planned hysterectomy, urethral or anterior\u002Fapical surgeries s requiring general anesthesia at the time of SUI treatment, during the last 6 months, or planned within the next 12 months.\n* Malignancy or history of radiation of the pelvis\n* Pregnant, post-partum, breast feeding or plans for pregnancy within 1 year\n* Incomplete emptying (PVR \\> 150mL)\n* Prior anti-incontinence procedure\n* Neurogenic bladder\n* Unwilling to continue current UUI treatment until completion of primary outcome at 12 months\n* Prior adverse reaction to synthetic mesh or urethral bulking material\n* Chronic bladder or pelvic pain conditions (e.g., Interstitial cystitis, painful bladder syndrome, fibromyalgia, chronic pelvic pain, etc.)\n* Active treatment for SUI with a pessary. For those using a pessary or other SUI support device, a 3-week washout period should occur prior to assessing baseline measures.","21 Years",{"count":254,"type":21},358,[53],"This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.\n\nThe Primary Aim is to determine the comparative effectiveness (as defined by \"much\" or \"very much\" better on PGI-I) of transurethral bulking agent (TBA) \\[for 1 or 2 injections in 12 months\\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).",[57,25,258],"Mixed Urinary Incontinence",[25,260,261,262],"Pelvic Floor Disorders","Single Incision Sling","Transurethral Bulking Agent","2026-06-04",{"date":203,"type":32},{"date":266,"type":32},"2024-08-28",{"date":268,"type":21},"2030-12-31",{"name":270,"class":271},"NICHD Pelvic Floor Disorders Network","NETWORK",7,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":219,"minAge":18,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":51,"phases":283,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":76},"100506789","phase-2-examining-the-effects-of-intra-detrusor-botox-at-time-of-holep-in-men-with-overactive-bladder-symptoms-100506789","NCT05878951","Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms","A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms","Inclusion Criteria:\n\n* Males 18 -89 undergoing HoLEP\n* Component of OAB symptoms including frequency, nocturia, urgency, and\u002For urge related incontinence\n* Willing to sign the Informed Consent Form\n* Able to read, understand, and complete patient questionnaires.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to OnabotulinumtoxinA injections\n* Patients having a concurrent ureteroscopy +\u002F- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP\n* Anticipated need for perineal urethrostomy at the time of HoLEP\n* Prior pelvic radiation or patients with a history of bladder cancer with or without BCG therapy\n* Patients who lack decisional capacity\n* Active urinary tract infection","89 Years",{"count":282,"type":21},66,[284,285],"PHASE2","PHASE3","The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.",[25,288,289,144],"Overactive Bladder Syndrome","Overactive Bladder","2026-06-02",{"date":263,"type":32},{"date":293,"type":32},"2023-07-13",{"date":295,"type":21},"2026-12-31",{"name":297,"class":75},"Northwestern University",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":191,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":51,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":328},"100626071","the-recover-study---postpartum-recovery-of-pelvic-floor-structures-and-the-impact-of-early-rehabilitation-100626071","NCT07430865","The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation","The RECOVER Study - Recovery of Pelvic Floor Structure and Function After Vaginal Childbirth- a Longitudinal Cohort Study With an Embedded Pilot Trial","RECOVER","Inclusion Criteria:\n\n* Individuals (over 18 years) who delivered a single child vaginally between 37 and 41 weeks of gestation, with a birthweight of at least 2500 grams.\n\nExclusion Criteria:\n\n* Delivered via c-section\n* Multiparous with previous third- or fourth-degree tears\n* History of major urogynecological surgery\n* Known neurological disorder (e.g., stroke, multiple sclerosis) that could affect the assessment outcomes\n* Severe connective tissue disorders that could affect the assessment outcomes\n* New pregnancy of more than 6 weeks during the study period\n* Pain with vaginal penetration, tampon use, or gynecological examinations that would prevent participation in assessments\n* Visible signs for wound complications assessed via REEDA tool (redness, oedema, ecchymosis, discharge, approximation) will exclude the participants from the first ultrasound assessment and vaginal palpation.",{"count":307,"type":21},380,[53],"The goal of this observational study with an embedded pilot clinical trial is to learn how the pelvic floor recovers after vaginal childbirth and whether early individualized pelvic floor muscle training can improve recovery in people who experience pelvic floor symptoms after vaginal delivery. The main questions it aims to answer are:\n\n* How do pelvic floor muscles and surrounding tissues change and recover during the first year after vaginal childbirth?\n* How are these structural changes and their recovery related to urinary, bowel, and vaginal symptoms?\n* In participants with pelvic floor symptoms after vaginal childbirth, does early individualized pelvic floor muscle training improve symptoms and support structural recovery compared with usual care?\n\nResearchers will compare participants who receive the early pelvic floor muscle training to those receiving standard postpartum care to see if the training helps improve pelvic floor function and reduce symptoms.\n\nParticipants will:\n\nAttend clinic visits at six weeks, and six months after childbirth\n\nComplete questionnaires about urinary, bowel, and vaginal symptoms, as well as physical activity and quality of life at six weeks, and four, six months, and twelve months after childbirth\n\nUndergo clinical pelvic floor assessments, including vaginal palpation of muscle strength, tone, and perineal body stability\n\nHave ultrasound examinations of the pelvic floor to assess muscle structure, tissue integrity, and perineal body morphology\n\nFor those in the pilot trial, participate in an early, individualized pelvic floor muscle training program\n\nThis study will provide important information about how the pelvic floor heals after childbirth, how structural changes are linked to symptoms, and whether early personalized training can help prevent long-term problems.",[25,311,312,313,314,315,316,317],"Pelvic Organ Prolapse (POP)","Bowel Symptoms","Postpartum","Physiotherapy and Rehabilitation","Pelvic Floor Muscle Training","Pelvic Floor","Recovery","2026-05-21",{"date":320,"type":32},"2026-05-27",{"date":322,"type":32},"2026-04-07",{"date":324,"type":21},"2029-12-31",{"name":326,"class":327},"Vastra Gotaland Region","OTHER_GOV",2,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":51,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":76},"100609811","implementing-a-mobile-health-application-for-women-veterans-with-urinary-incontinence-myhealthebladder-function-queri-30-100609811","NCT07219433","Implementing a Mobile Health Application for Women Veterans With Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0","Implementing a Mobile Health Application for Women Veterans With Urinary Incontinence: MyHealtheBladder in Function QUERI 3.0 (QUE 25-008)","MHB","Inclusion Criteria:\n\nSite Inclusion Criteria:\n\n* Facility is part of the U.S. Department of Veterans Affairs (VA) health system.\n* Clinic serves at least 100 Women Veterans annually.\n* Identified site champion (e.g., clinician or staff member) who is willing to assume required program responsibilities for implementation.\n\nPatient Inclusion Criteria:\n\n* Women Veterans\n* Have any type of Urinary Incontinence existing for at least 3 months\n\nExclusion Criteria:\n\nSite Exclusion Criteria:\n\n* Clinic has already implemented the MyHealtheBladder program.\n\nPatient Exclusion Criteria:\n\n* No access to computer or mobile device\n* No email account\n* Institutionalized",{"count":338,"type":21},20,[53],"Implementing a Mobile Health Application for Women Veterans with Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0 aims to compare implementation approaches while also gathering information on clinical effects of the Evidence-Based Program (EBP) in its new context and focusing on equitable reach (extent to which the program serves all members of its intended audience). The overall goal is to implement, evaluate, and sustain MyHealtheBladder in 20 VA facilities using a type III effectiveness-implementation hybrid study framework and parallel cluster randomized trial (CRT) design.",[25],[343,344,345,346,347],"Veterans","Implementation Science","Functional Status","Quality of Life","Mobile Applications",{"date":349,"type":32},"2026-05-22",{"date":351,"type":32},"2026-04-30",{"date":353,"type":21},"2030-09-30",{"name":355,"class":356},"VA Office of Research and Development","FED",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":83,"minAge":4,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":155},"100541933","nxt-post-market-clinical-follow-up-100541933","NCT06336304","NXT Post-Market Clinical Follow-up","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation","Inclusion Criteria:\n\n* Patients medically indicated for urodynamic study\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n\nExclusion Criteria:\n\n* Patients or legally authorized representative with cognitive or psychiatric condition that interferes with or precludes direct and accurate communication regarding the study, giving informed consent or ability to complete the patient questionnaire\n* Patients with confirmed active bladder infections (not including patients with asymptotic bacteria)\n* Pregnant women\n* Patients with recent (less than 2 weeks) pelvic floor surgery\n* Requires use of suprapubic catheter",{"count":365,"type":21},180,"NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations",[25,368,369,370,371],"Urinary Obstruction","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Incontinence, Urge","2026-05-13",{"date":374,"type":32},"2026-05-15",{"date":376,"type":32},"2024-06-18",{"date":378,"type":21},"2027-03",{"name":380,"class":39},"Laborie Medical Technologies Inc.",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":51,"phases":390,"briefSummary":391,"conditions":392,"keywords":396,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":76},"100544518","tens-analgesia-during-outpatient-urethral-bulking-for-stress-urinary-incontinence-100544518","NCT06369922","TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","Transcutaneous Electrical Nerve Stimulation Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","TENSUB","Inclusion Criteria:\n\n* • Women, Age ≥18 years\n\n  * Diagnosis of SUI\n  * Scheduled to undergo transurethral bulking in the office\n  * Able to read\u002Fwrite English\n\nExclusion Criteria:\n\n* • Cutaneous damage such as ulcers or broken skin on target treatment area\n\n  * Currently implanted cardiac pacemaker or defibrillator\n  * Pre-procedural use of opioids for pain management, less than 8 hours from last dose\n  * Participants with altered sensation below the umbilicus",{"count":221,"type":21},[53],"This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia, and the second group will have the cystoscopy with placebo TENS.",[393,25,56,394,395],"Stress Incontinence Female","Pain","Pain Acute",[397,398,399],"TENS","pain","Transcutaneous Electrical Nerve Stimulation Analgesia","2026-05-11",{"date":372,"type":32},{"date":403,"type":32},"2024-07-01",{"date":405,"type":21},"2027-06-01",{"name":407,"class":75},"University of Rochester",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":191,"sex":17,"minAge":415,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":51,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":76},"100637268","effects-of-paula-exercises-and-tibial-nerve-stimulation-in-stress-urinary-incontinence-100637268","NCT07576205","Effects of Paula Exercises and Tibial Nerve Stimulation in Stress Urinary Incontinence","Combine Effects of Paula Exercises and Tibial Nerve Stimulation on Incontinence, Pelvic Floor Muscles Strength, Sexual Function and Quality of Life in Stress Urinary Incontinence","Inclusion Criteria:\n\n* Multiparous women (≥2 full-term vaginal deliveries)\n* Clinical diagnosis of stress urinary incontinence (confirmed by cough stress test)\n* Duration of symptoms ≥3 months\n* Ability to correctly perform pelvic floor contractions (confirmed by digital examination)\n\nExclusion Criteria:\n\n* Neurological disorders (e.g., multiple sclerosis, spinal cord injury)\n* Mixed or urge urinary incontinence as the predominant type\n* Previous pelvic surgery or incontinence-related procedures within the past year\n* Current pregnancy or \\\u003C6 months postpartum\n* Pelvic organ prolapse beyond stage II (POP-Q system)\n* Current use of other incontinence therapies (e.g., medication, PTNS, PFMT)\n* Diagnosed malignancy\n* Diagnosed psychiatric disorder\n* Pregnancy\n* Diagnosed dermatological condition\n* Participants who are currently enrolled in other clinical trials to avoid potential confounding factors.","30 Years","45 Years",{"count":418,"type":21},52,[53],"The aim of this study is to compare the combined effects of Paula method \\& tibial nerve stimulation on incontinence, pelvic floor muscles strength, sexual function and quality of life in stress urinary incontinence",[25],[423,424,316,425,426,57],"Tibial Nerve","Incontinence","Quality of life","Female","2026-05-04",{"date":429,"type":32},"2026-05-08",{"date":431,"type":32},"2025-10-01",{"date":68,"type":21},{"name":434,"class":75},"Riphah International University",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":442,"enrollmentInfo":443,"targetDuration":4,"studyType":51,"phases":445,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":76},"100205612","phase-1-muscle-fiber-fragment-treatment-for-urinary-incontinence-100205612","NCT01953263","Muscle Fiber Fragment Treatment for Urinary Incontinence","A Phase 1 Study of Human Muscle Fiber Fragment (MFF) Treatment for Urinary Incontinence","Inclusion Criteria:\n\n* Adult female patients who are not pregnant or lactating\u002Fbreast-feeding and must be either not sexually active, surgically sterilized, or must be practicing an effective method of birth control as determined by the investigator\n* Patients between the ages of 18 and 75 years\n* Patients with positive diagnosis of urinary incontinence due to sphincter insufficiency caused by acquired (e.g., stress urinary incontinence) and\u002For congenital conditions.\n* Patients with cystometric capacity of bladder \\> 100 ml\n* Patients with normal renal function\n* Patients with a history of primary incontinence\n\nExclusion Criteria:\n\n* Patients with a history of hypercontractile bladder, non-compliant bladder, hydronephrosis or neurogenic bladder\n* Patients with an active urinary tract infection as evidenced by positive urine culture\n* Patients who are taking medication that affect urination such as prescription drugs, over-the-counter drugs, or dietary supplements, including herbal supplements and those taken with teas\n* Patients requiring concomitant use of or treatment with immunosuppressive agents\n* Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study\n* Patients with evidence or diagnosis of any primary muscle disease or coagulation disorder (including concomitant anti-coagulation therapy)\n* Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study\n* Patients who have been treated with any cellular therapy within 12 months prior to enrollment in this study\n* Patients with urinary incontinence other than the categories being investigated\n* Patients with significant (\\>grade 2) pelvic organ prolapse\n* Patients with vaginal prolapse beyond introitus\n* Patients with neurological disorders\n* Patients with abnormal bladder capacity (i.e., less than 100 cc)\n* Patients with abnormal urologic conditions, including post-void residual, urethral stricture and bladder neck contracture, spastic bladder, vesicoureteral reflux, bladder stones, bladder tumors, hydronephrosis, other renal impairment","75 Years",{"count":444,"type":21},10,[446,284],"PHASE1","This study is designed to evaluate the safety of autologous muscle fiber fragments for the treatment of urinary incontinence due to incompetent outlet (bladder neck\u002Furethra).",[25],[450],"urinary incontinence, muscle fibers","2026-04-22",{"date":453,"type":32},"2026-04-23",{"date":455,"type":4},"2016-01",{"date":457,"type":21},"2028-12",{"name":459,"class":75},"Wake Forest University",{"id":461,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":463,"keywords":464,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":76},"100635658",{"count":20,"type":21},[25],[27],"2026-04-21",{"date":467,"type":32},"2026-04-29",{"date":469,"type":21},"2026-04",{"date":471,"type":21},"2026-11",{"name":38,"class":39},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":191,"sex":83,"minAge":480,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":484,"conditions":485,"keywords":490,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":40},"100634125","the-voided-urinary-perineal-and-faecal-microbiota-among-children-and-adolescents---the-ppuf-study-100634125","NCT07535619","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents - the PpUF-study.","The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children and Adolescents - the PpUF-study.","Inclusion Criteria:\n\n* Overactive bladder as per International Children's Continence Society criteria (cases only).\n* At least two wet days per week (cases only).\n* No prior pharmacological treatment of OAB and DUI (cases only).\n* No lower urinary tract symptoms (healthy participants only).\n* Negative urine dipstick test\n\nExclusion Criteria:\n\n* No known urogenital abnormality affecting the lower urinary tract function.\n* No known gastrointestinal or neurological diseases.\n* No use of systemic drugs within five half-lives of the drug.\n* No use of systemic antibiotics within three months before inclusion\n* No current urinary tract infection.\n* No urinary tract infection within the last three months prior to inclusion.\n* No current constipation.\n* Abnormal uroflowmetry (healthy participants only).","5 Years","17 Years",{"count":483,"type":21},110,"The aim of this study is to investigate whether the voided urinary, perineal\u002Fpreputial, and the fecal microbiota are different between children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the study aims to investigate if the microbiota is different according to the severity of DUI and if the microbiota is changed throughout treatment of DUI. A follow-up study will as well be performed on healthy children to investigate how the microbiota evolves with increasing age and pubertal stage. Children with OAB and DUI will be recruited from involved pediatric departments, and specimen in the form of urine, perineal\u002Fpreputial swabs, and feces will be collected according to the protocol.",[25,486,142,144,145,487,488,489],"Daytime Wetting","Urological Manifestations","Elimination Disorders","Behavioral Symptoms",[491,492,493,494],"Voided Urinary Microbiota","Perineal Microbiota","Fecal Microbiota","Illumina MiSeq Sequencing","2026-04-15",{"date":497,"type":32},"2026-04-17",{"date":499,"type":32},"2022-12-14",{"date":501,"type":21},"2028-06",{"name":503,"class":75},"Aalborg University Hospital",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":191,"sex":83,"minAge":511,"maxAge":512,"enrollmentInfo":513,"targetDuration":4,"studyType":51,"phases":515,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":40},"100515295","brain-activity-among-children-with-overactive-bladder-and-daytime-urinary-incontinence-and-healthy-children-100515295","NCT05989646","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children","Brain Activity Among Children With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children, and Modulation of Brain Activity by Transcutaneous Electrical Nerve Stimulation - a Functional Magnetic Resonance Imaging Study","Inclusion Criteria:\n\n* Overactive Bladder as per International Children's Continence Society criteria (cases only).\n* At least 2 incontinence episodes per week (cases only).\n* No urinary tract symptoms (healthy participants only).\n* More than 3 daily urinations.\n* Normal clinical examination.\n\nExclusion Criteria:\n\n* Known urogenital abnormality affecting the lower urinary tract function.\n* Prior surgery in the urinary tract (except circumcision).\n* Known neurological diseases or prior cerebral surgery.\n* Known neuropsychiatric disorders or suspicion of those by screening.\n* Treatment with pharmacological agents affecting the brain function.\n* Prior treatment with Enuresis Alarm or Transcutaneous Electrical Nerve Stimulation.\n* Prior or current treatment with mirabegron or oxybutynin.\n* Current urinary tract infection.\n* Current constipation according to Rome IV-criteria or faecal incontinence.\n* Claustrophobia.\n* Metallic items in the body contraindicating MRI-scans.\n* Abnormal uroflowmetry (healthy participants only).","6 Years","14 Years",{"count":514,"type":21},65,[53],"The aim of this study is to investigate whether the activity in brain areas controlling the bladder is different among children suffering from Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy children without bladder symptoms. Moreover, the aim is to investigate if sacral transcutaneous electric nerve stimulation (TENS) has a central mechanism of action. Children with OAB and DUI will be recruited from involved pediatric departments, and functional magnetic resonance imaging (fMRI) will be performed before and after 10 weeks of sacral TENS. In healthy children without bladder symptoms, only the baseline fMRI will be performed.",[25,486,142,143,144,145,487,489,518,488],"Mental Disorders",[520,397,521,522],"Transcutaneous Electrical Nerve Stimulation","Functional Magnetic Resonance Imaging","fMRI",{"date":524,"type":32},"2026-04-20",{"date":526,"type":32},"2021-05-05",{"date":241,"type":21},{"name":503,"class":75},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":536,"maxAge":193,"enrollmentInfo":537,"targetDuration":4,"studyType":51,"phases":539,"briefSummary":540,"conditions":541,"keywords":543,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":76},"100632954","combined-effects-of-swiss-ball-exercises-and-diaphragmatic-breathing-in-pregnant-females-100632954","NCT07520396","Combined Effects of Swiss Ball Exercises and Diaphragmatic Breathing in Pregnant Females","Combined Effects of Swiss Ball Exercises and Diaphragmatic Breathing on Stress Urinary Incontinence, Pelvic Floor Muscle Strength and Quality of Life in Pregnant Females.","Inclusion Criteria:\n\n* • Females with singleton pregnancy\n\n  * Females with urinary incontinence\n  * Age range between 20-40\n  * Females with diagnosed with mild to moderate stress urinary incontinence\n  * Females with weak pelvic floor muscles\n\nExclusion Criteria:\n\n* • Females who are not pregnant\n\n  * Females who have had any previous history of hysterectomy\n  * Females with placenta previa\n  * Females with UTI\n  * Females with preterm labor\n  * Females with pelvic organ prolapse","20 Years",{"count":538,"type":21},42,[53],"30 to 60 percent of the pregnant females experience stress urinary incontinence depending on various factors like trimester, parity and body weight. Stress urinary incontinence is a common yet often underreported condition affecting pregnant women, characterized by involuntary leakage of urine during physical activities such as coughing, sneezing, or exercising. Stress urinary incontinence majorly occurs due to increased intra-abdominal pressure and weakened pelvic floor muscles which are further strained during pregnancy. Despite its impact on quality of life, awareness and management remains inadequate. Strengthening the pelvic floor muscles plays a critical role in managing stress urinary incontinence and Swiss ball exercises have emerged as an effective and low impact method to improve core stability and pelvic floor muscle strength. These exercises engage deep abdominal and pelvic muscles in a functional and dynamic way, potentially enhancing both physical and psychological well-being during pregnancy.\n\n. The study will be conducted as a randomized control trial involving females with stress urinary incontinence in Zia Hospital Lahore and Ittefaq Hospital Lahore. The study will be completed within 10 months of synopsis approval. A non-probability sampling technique will be employed and 42 patients will be enrolled after randomization. Participants will be divided into two groups. Group A will undergo a structured program involving Swiss ball exercises combined with diaphragmatic breathing. Group B will receive Swiss ball exercises without diaphragmatic breathing. Kegel exercises will be considered the baseline treatment. Outcome measures will include syptoms of stress urinary incontinence (using International Consultation Incontinence Questionnaire), pelvic floor muscle strength (assessed through standardized tools i.e. Modified Oxford Scale) and self-reported quality of life (using validated questionnaires i.e. King's Health Questionnaire). The data collected will be analyzed using IBM SPSS statistics version 25.",[25,542,346],"Muscle Strength",[544,545,546,547,548],"swiss ball exercises","diaphragmatic breathing","quality of life","pelvic floor muscle strength","stress urinary incontinence","2026-04-02",{"date":551,"type":32},"2026-04-09",{"date":553,"type":32},"2025-08-31",{"date":555,"type":21},"2026-09-30",{"name":434,"class":75},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":51,"phases":566,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":328},"100631468","phase-4-prophylactic-antibiotics-for-outpatient-urethral-bulking-100631468","NCT07501065","Prophylactic Antibiotics for Outpatient Urethral Bulking","Prophylactic Antibiotics for Outpatient Urethral Bulking: Impact on Post-Procedural Urinary Tract Infection Rates","Inclusion Criteria:\n\n* Women ≥ 18 years of age.\n* Patients evaluated by a pelvic floor specialist (either urogynecologist or urologist) at the University of Miami with plans to undergo urethral bulking with Bulkamid for stress urinary incontinence or mixed urinary incontinence (stress predominant).\n* Negative testing for UTI in pre-procedural work-up (including either negative urine culture or urine dip negative for infection).\n* Post-void residual volume of 150 mL or less (measured by either catheterization or bladder scan)\n* Fluent in English or Spanish\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Contraindications to both oral antibiotics including antibiotic allergies or significant renal disease (GFR \\\u003C30)\n* Patient undergoing additional pelvic organ prolapse procedures or other urologic procedures concomitantly\n* Recurrent UTIs, defined as 3 or more UTIs within the past 12 months or 2 UTIs within the past 6 months\n* Patients currently taking daily antibiotic prophylaxis for any reason\n* Pelvic organ prolapse stage greater than 2\n* Patients with immunosuppression due to underlying medical conditions\n* Patients who are pregnant\n* Recent antibiotic treatment within one week of the procedure\n* Unable or unwilling to provide informed consent or complete study procedures",{"count":565,"type":21},150,[567],"PHASE4","The purpose of this study is to evaluate whether taking prophylactic (preventative) antibiotics at the time of standard of care clinic-based urethral bulking reduces the risk of post-procedural urinary tract infection (UTI).",[570,57,25],"Urinary Tract Infections","2026-03-24",{"date":573,"type":32},"2026-03-30",{"date":575,"type":21},"2026-06",{"date":457,"type":21},{"name":578,"class":75},"University of Miami",{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":191,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":587,"conditions":588,"keywords":593,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":600,"leadSponsor":602,"locationsCount":4},"100629706","maternal-musculoskeletal-factors-of-the-hip-lumbopelvic-abdominal-and-pelvic-floor-regions-and-their-association-with-mode-of-delivery-and-postpartum-pelvic-floor-dysfunction-100629706","NCT07478159","Maternal Musculoskeletal Factors of the Hip, Lumbopelvic, Abdominal and Pelvic Floor Regions and Their Association With Mode of Delivery and Postpartum Pelvic Floor Dysfunction","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Singleton pregnancy\n* Gestational age of 36 weeks at the time of the baseline assessment\n* Receiving prenatal care in primary healthcare centers of Zaragoza (Spain)\n* Ability to understand study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* High-risk pregnancy conditions that may affect labor progression or maternal musculoskeletal assessment (e.g., severe obstetric complications requiring planned cesarean section)\n* Previous pelvic floor surgery\n* Neurological or musculoskeletal disorders affecting the lumbopelvic or pelvic floor region\n* Inability to complete the assessment protocol or questionnaires",{"count":586,"type":21},376,"This prospective observational cohort study aims to investigate the association between maternal musculoskeletal factors of the hip, lumbopelvic, abdominal, and pelvic floor regions and childbirth outcomes, as well as their consequences on pelvic floor function during the postpartum period. A total of 376 pregnant women will be recruited at 36 weeks of gestation and followed until 12 weeks postpartum. Musculoskeletal assessments will include hip range of motion, lumbopelvic mobility, abdominal muscle function, and pelvic floor strength and morphology. Obstetric outcomes such as mode of delivery and perineal trauma will be recorded after childbirth. The study will analyze whether maternal musculoskeletal function during late pregnancy is associated with delivery mode and pelvic floor dysfunction in the postpartum period.",[260,25,589,590,591,592],"Perineal Trauma","Pelvic Floor Dysfunction","Pregnancy","Puerperium",[260,594,595,25],"Obstetric Labor","Complications Perineal Trauma","2026-03-12",{"date":598,"type":32},"2026-03-17",{"date":100,"type":21},{"date":601,"type":21},"2028-01-01",{"name":603,"class":75},"Universitat Internacional de Catalunya",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":219,"minAge":18,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":613,"conditions":614,"keywords":616,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":76},"100595172","tolerance-use-and-performance-of-the-peasy-urine-collection-device-in-hospitalized-patients-100595172","NCT07028996","Tolerance, Use and Performance of the PEASY Urine Collection Device in Hospitalized Patients","Clinical Investigation Plan for Non-CE-marked Medical Device Without Marking Objective (Category 4.4) to Evaluate Tolerance, Use and Performance of a Urine Collection Device (PEASY), in Hospitalized Patients: First-in-man Pilot Study","TUPELO","Inclusion Criteria:\n\n* Patients requiring non-invasive urine collection.\n* Incontinent patient for whom the use of a penile pouch to control leakage has been suggested by the care team.\n* Uncircumcised patient.\n* Patient with no physical anomaly preventing complete unhooding (phimosis, micropenis, penile invagination, etc.).\n* Patient with no apparent irritation or infection of the glans (mycosis, herpetic lesion, etc.).\n* Patient is conscious and able to answer simple questions.\n* Patient has given free and informed consent.\n* Patient has signed the consent form.\n* Patient affiliated or beneficiary of a health insurance plan.\n\nExclusion Criteria:\n\n* Patient participating in another high-risk interventional study.\n* Patient in an exclusion period determined by another study.\n* Patient under court protection, guardianship or curatorship.\n* Patient unable to give consent.\n* Patient for whom it is impossible to give informed information.\n* Circumcised patients.",{"count":338,"type":21},"At present, 3 types of urine collection device can be distinguished: absorbent devices (diaper-type), penile clamps and penile collection sheaths. Both pads and penile sheaths are used depending on the department concerned, the clinical context and user preferences. A 2023 survey at Nîmes University Hospital showed that penis sleeves have undesirable side effects like fixation problems and pain on removal, and care assistants reported penile irritation caused by the penis sleeve. Caregivers also reported difficulties when handling and using penis sleeves.\n\nThere is clearly a need for a better device.To overcome the disadvantages of penis covers, the PEASY project team at Nîmes University Hospital has developed a practical, non-invasive medical device for eliminating urine, positioned on the glans: the PEASY device. This device is held in place by a non-adhesive fastening system that involves the foreskin, to ensure leakage-free urine flow.",[25,615],"Medical Device Discomfort",[200,617,618],"Penile clamp","Urinary sheath","2026-03-10",{"date":596,"type":32},{"date":622,"type":32},"2025-07-16",{"date":624,"type":21},"2027-01-15",{"name":626,"class":75},"Centre Hospitalier Universitaire de Nīmes",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":191,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":51,"phases":637,"briefSummary":638,"conditions":639,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":328},"100467095","phase-4-treating-incontinence-for-underlying-mental-and-physical-health-100467095","NCT05362292","TReating Incontinence for Underlying Mental and Physical Health","Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence","TRIUMPH","Inclusion Criteria:\n\n* Aged 60 years or older at the time of enrollment\n* Female sex at birth, without surgical or hormonal gender re-assignment therapy\n* Able to walk to the bathroom and use the toilet without assistance\n* Report urinary incontinence starting at least 3 months prior to screening\n* Report that at least half of incontinence episodes occur with a sudden or strong sensation of urgency\n* Report 2 or more urgency incontinence episodes over a 7-day period\n* Willing to provide informed consent and adhere to study procedures throughout the length of the study\n\nExclusion Criteria:\n\n* Prior clinician diagnosis of dementia, or a Montreal Cognitive Assessment (MOCA) score of 17 or lower on screening cognitive evaluation\n* Current use of anticholinergic, beta-3-adrenergic agonist, or other medication designed to improve urgency incontinence symptoms, or use in the past 1 month\n* Initiation, discontinuation, or dose change of dementia medications (such as donepezil, galantamine, memantine, rivastigmine) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs with strong anticholinergic effects (based on the Beers List) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs that can affect urinary frequency, including diuretics, in the past 1 month (but candidates on stable doses are eligible)\n* Current urinary tract infection (UTI) based on screening urinalysis and culture (but candidates can re-present for re-screening after undergoing treatment for UTI)\n* History of allergy or sensitivity to either of the study medications or an ingredient in the placebo or study medication capsule\n* Severe hepatic impairment (Child-Pugh score B or greater) or renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin) as a contraindication to both study medications\n* Current bladder obstruction or urinary retention (defined by symptoms suggesting difficulty emptying the bladder in addition to postvoid residual urine volume greater than 150 cc by portable bladder ultrasound)\n* Uncontrolled hypertension (based on measured systolic blood pressure greater than 180 or diastolic blood pressure greater than 110 mmHg) as a contraindication to beta-3-adrenergic therapy\n* Self-reported history of gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe ulcerative colitis, or toxic megacolon as contraindications for anticholinergic bladder therapy\n* Use of drugs with adverse interactions with one of the study medications in the past 1 month, including potent CYP3A4 inhibitors, hepatic enzyme metabolism inducers, narrow therapeutic index drugs metabolized by CYP2D6, or intention to start taking one of these medications during the study treatment period\n* History of bladder surgery, invasive intra-vesical therapy, or bulk bladder injections in the past 3 months (more remote surgery will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Use of other specialized incontinence therapy (electrostimulation, pelvic physiotherapy, formal behavioral therapy overseen by certified practitioners) in the past 3 months (more remote therapy will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Inability to sign informed consent or complete questionnaires, interviews, or study testing in English\n* Other condition that would prevent the participant from completing study procedures, in the opinion of the investigators (e.g., uncontrolled psychosis)",{"count":636,"type":21},270,[567],"The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.",[371,25,289,640,641,424],"Incontinence, Urge","Incontinence, Urinary","2026-03-04",{"date":644,"type":32},"2026-03-06",{"date":646,"type":32},"2022-10-04",{"date":648,"type":21},"2027-08-02",{"name":650,"class":75},"University of California, San Francisco",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":51,"phases":659,"briefSummary":660,"conditions":661,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":76},"100580715","phase-2-cbd-for-lower-urinary-tract-dysfunction-in-spinal-cord-injury-100580715","NCT06840899","CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury","Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury","Inclusion Criteria:\n\n* \\>18 years of age\n* History of supra-sacral spinal cord injury of any mechanism\n* Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock)\n* Willingness to participate in drug intervention trial\n* English-speaking (able to provide consent and complete questionnaires)\n\nExclusion Criteria:\n\n* History of intravesical Botox\n* Actively taking \\>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms\n* Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported\n* Thought or mood disorder aside from depression",{"count":338,"type":21},[284],"The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI).\n\nParticipants will take Epidiolex (purified CBD) for 90 days",[662,663,25],"Supra-sacral Spinal Cord Injury","Spinal Cord Injury","2026-03-02",{"date":642,"type":32},{"date":667,"type":32},"2026-02-13",{"date":669,"type":21},"2027-05",{"name":671,"class":75},"University of Wisconsin, Madison"]